Charles Dadswell's insider trading at Illumina
SEC Form 4 filings for Dadswell Charles, 5200 Illumina Way, San Diego, CA 92122, USA

Insider trading of Charles Dadswell, a Sr VP & General Counsel at ILMN Illumina, Inc.

Most recently Charles Dadswell sold 145 shares worth $32,552.50 on 3 January 2018.

Date
#
Company
Insider Title
Trans.
Transaction
Shares Price per share Total price Shares after Source
2018-01-03 Charles Dadswell
Sr VP & General Counsel
Sr VP & General Counsel Sale 145 $224.50 $32,552.50
2018-01-03
7,411 SEC insider form 4
2017-12-04 Charles Dadswell
Sr VP & General Counsel
Sr VP & General Counsel Sale 145 $225.33 $32,672.85
2017-12-04
6,388 SEC insider form 4
2017-11-03 Charles Dadswell
Sr VP & General Counsel
Sr VP & General Counsel Sale 1,609 $207.88 $334,478.92
2017-11-03
7,217 SEC insider form 4
2017-10-03 Charles Dadswell
Sr VP & General Counsel
Sr VP & General Counsel Sale 145 $202.23 $29,323.35
2017-10-03
8,826 SEC insider form 4
2017-09-05 Charles Dadswell
Sr VP & General Counsel
Sr VP & General Counsel Sale 145 $205.71 $29,827.95
2017-09-05
8,971 SEC insider form 4
2017-08-03 Charles Dadswell
Sr VP & General Counsel
Sr VP & General Counsel Sale 1,609 $197.00 $316,973.00
2017-08-03
9,037 SEC insider form 4
2017-07-03 Charles Dadswell
Sr VP & General Counsel
Sr VP & General Counsel Sale 145 $174.24 $25,264.80
2017-07-03
10,646 SEC insider form 4
2017-06-05 Charles Dadswell
Sr VP & General Counsel
Sr VP & General Counsel Sale 145 $184.75 $26,788.75
2017-06-05
10,791 SEC insider form 4
2017-05-03 Charles Dadswell
Sr VP & General Counsel
Sr VP & General Counsel Sale 1,609 $187.07 $300,995.63
2017-05-03
10,936 SEC insider form 4
2017-02-15 Charles Dadswell
Sr VP & General Counsel
Sr VP & General Counsel Option exercise 7,032 $0.00 $0.00
2017-02-15
14,699 SEC insider form 4
2017-02-06 Charles Dadswell
Sr VP & General Counsel
Sr VP & General Counsel Sale 572 $161.26 $92,240.72
2017-02-06
7,592 SEC insider form 4
2017-01-10 Charles Dadswell
Sr VP & General Counsel
Sr VP & General Counsel Sale 116 $161.60 $18,745.60
2017-01-10
8,420 SEC insider form 4

Illumina, Inc. provides sequencing and array-based solutions for genetic analysis. The company's sequencing by synthesis technology provides researchers with various applications and the ability to sequence mammalian genomes. It also offers arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow for the detection of known genetic markers on a single array. In addition, the company provides various library preparation and sequencing kits to simplify workflows and accelerate analysis; and genome sequencing, genotyping, and non-invasive prenatal testing services. It serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as through life-science distributors. It has collaboration agreements with IBM Watson Health to access genome data interpretation by integrating Watson for genomics into Illumina's BaseSpace Sequence Hub and tumor sequencing process; and NRGene to develop new molecular breeding tools for cattle to support global food production. The company also has a co-development agreement with Munich Leukemia Laboratory GmbH and IBM Watson Health to build a cognitive technology prototype to help researchers improve leukemia treatment. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.

  • Illumina, Inc., 5200 Illumina Way, San Diego 92122, United States
  • illumina.com
  • 858-202-4500